Department of Pediatric Oncology/Pediatric Bone Marrow Transplantation Unit, Cukurova, University, Faculty of Medicine, Adana, Turkey.
J Pediatr Hematol Oncol. 2020 Nov;42(8):e738-e744. doi: 10.1097/MPH.0000000000001940.
Febrile neutropenia (FEN) is a significant side effect after chemotherapy, and it is known that using granulocyte colony-stimulating factor (G-CSF) has positive effects on treatment results. In this study, the effects of different G-CSF doses (5 to 10 mcg/kg/day) on treatment results in patients with high-risk FEN were evaluated. A total of 124 high-risk FEN episodes of 62 patients were enrolled in the study between June 2017 and October 2018. The episodes were divided into 2 groups according to G-CSF treatment doses, they received from 5 to 10 mcg/kg/day. The clinical characteristics of the patients, the treatments they received, laboratory findings, microbiologic results, and cost analysis were recorded. No statistically significant difference was found between 2 groups in terms of the mean duration of recovery from neutropenia, duration of fever, total length of hospital stay, duration of FEN episode, duration of G-CSF use, costs, bacteremia frequency, and other treatments. In patients with solid tumors, the cost of filgrastim was significantly higher in the high-dose G-CSF group. Using different doses of G-CSF in high-risk FEN episodes did not show any different effects on clinical and treatment results. The dose of 5 mcg/kg/day would be more appropriate in FEN treatment.
发热性中性粒细胞减少症（FN）是化疗后的一种严重副作用，已知使用粒细胞集落刺激因子（G-CSF）对治疗结果有积极影响。在这项研究中，评估了不同剂量的 G-CSF（5 至 10mcg/kg/天）对高危 FN 患者治疗结果的影响。2017 年 6 月至 2018 年 10 月，共有 62 名患者的 124 例高危 FN 发作被纳入该研究。根据 G-CSF 治疗剂量将发作分为 2 组，他们分别接受 5 至 10mcg/kg/天的治疗。记录了患者的临床特征、接受的治疗、实验室检查结果、微生物学结果和成本分析。两组患者从中性粒细胞减少症恢复的平均时间、发热持续时间、总住院时间、FN 发作持续时间、G-CSF 使用时间、成本、菌血症频率和其他治疗方面无统计学差异。在实体瘤患者中，高剂量 G-CSF 组的非格司亭费用明显更高。在高危 FN 发作中使用不同剂量的 G-CSF 对临床和治疗结果没有显示出任何不同的影响。5mcg/kg/天的剂量在 FN 治疗中可能更合适。
